Opinion on Pharmaceuticals and Healthcare

Published within

« | ... | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2012: standout schizophrenia and bipolar depression data for Latuda steal the show

New clinical data were presented at APA 2012 that showed that Latuda is effective as an adjunctive treatment for bipolar depression and may possess a procognitive effect in schizophrenia patients. These findings set Latuda apart from the competition and may allow the drug to shine in a fiercely competitive antipsychotics market.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: diagnostic overhaul will shape psychiatry drug markets

The DSM-5, the latest edition of the gold-standard diagnostic guidelines in psychiatry throughout the world, is due to be unveiled in May 2013. Given the huge size of the psychiatry drug market, any changes made to the diagnoses of conditions such as depression, bipolar disorders, and schizophrenia - however slight - will be of great interest to the pharmaceutical industry.

Published By Datamonitor
15 May 2012
Expert View
Expert View

APA 2012: Forest's latest antidepressants will have diverging fortunes

Pooled data released at the APA 2012 suggest that Forest's Viibryd combines a fast onset of antidepressant activity with a favorable side-effect profile, satisfying two important unmet needs in depression pharmacotherapy. Conversely, results from the Phase III program for levomilnacipran are less impressive, suggesting that the drug offers little benefit over other drugs in its class.

Published By Datamonitor
15 May 2012
Expert View
Expert View

Arena Pharmaceuticals: positive vote for Lorqess, but will commercial success follow?

Lorqess has moved one step closer to approval for the treatment of obesity following a positive review by the FDA advisory committee. The result came as a surprise to some, after the drug was rejected in 2010 due to safety concerns. Despite the good news for Arena Pharmaceuticals, the drug's commercial prospects remain uncertain: the path to launch is unclear, and uptake may be slow.

Published By Datamonitor
15 May 2012
CommentWire
CommentWire

Lundbeck: Alzheimer's success may herald a new drug class

Lundbeck has secured another success in its pipeline as Lu AE58054 met its primary cognition endpoint in a Phase II study in moderate Alzheimer's disease. The drug, a 5-HT6 receptor antagonist, looks set to rival GlaxoSmithKline's SB-742457 as a novel class of Alzheimer's disease drugs races to the reach the market.

Published By Datamonitor
29 May 2012
CommentWire
CommentWire

Genzyme/Sanofi: Aubagio's TOWER results fail to rise above the competition

New positive data from a pivotal Phase III trial of Genzyme's Aubagio will serve to support its anticipated approval in the US and EU, demonstrating significant reduction in annualized relapse rate. Despite these positive results, the drug will still face fierce competition from marketed oral Gilenya and Biogen's pipeline oral candidate BG-12, given their far superior efficacy profiles.

Published By Datamonitor
06 Jun 2012
CommentWire
CommentWire

GlaxoSmithKline/XenoPort: generic competition and safety warnings cast mist over Horizant's horizons

Horizant's approval by the FDA offers patients with postherpetic neuralgia an improved dosing regimen over available treatment options. However, Horizant will face fierce competition in the US from generic gabapentin and the once-daily gabapentin formulation Gralise (Depomed). Moreover, safety warnings surrounding significant driving impairment are likely to serve as a deterrent to prescribing.

Published By Datamonitor
11 Jun 2012
CommentWire
CommentWire

Genentech/Roche: trial success prompts Perjeta approval

Genentech, a member of the Roche Group, has announced FDA approval of Perjeta in combination with Herceptin and docetaxel for the treatment of HER2-positive metastatic breast cancer. Perjeta's approval will enhance Roche's extensive portfolio of HER2-targeted therapies and help maintain sales revenue after Herceptin's patent expires.

Published By Datamonitor
13 Jun 2012
Expert View
Expert View

Johnson & Johnson: can canagliflozin do what dapa didn't?

New clinical trial data for canagliflozin have revealed that its blood glucose-lowering abilities show superiority to blockbuster gold-standard Januvia, with the added benefit of weight loss. The potential for first-to-market SGLT-2 inhibitor status in the US and its good safety and efficacy profile boost canagliflozin's chances for success in a crowded diabetes market.

Published By Datamonitor
14 Jun 2012
CommentWire
CommentWire

Proteolix/Onyx Pharmaceuticals: Kyprolis recommendation may threaten Velcade in myeloma

The FDA's ODAC has recommended Kyprolis, the multiple myeloma treatment from Proteolix and Onyx Pharmaceuticals, despite ongoing cardiac and hepatic toxicity concerns. If approved, the drug will threaten Velcade's share of the myeloma market and could pose a threat to Johnson & Johnson's future revenues.

Published By Datamonitor
21 Jun 2012

« | ... | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | » »|

No help is available.